Unresolved
We still don’t know whether anyone at this organisation has actually used this technology — zero lived-experience observations exist.
Not yet answered
What are we missing?
HealthAratus Intelligence
Nanox
NanoxNanox Intelligence
What the accumulated evidence, deployment record and lived experience actually show.
Intelligence lenses
Four ways of interrogating the same reality. Each changes the question, not the subject.
Do published findings about Nanox match what happens in practice?
Public evidence
Automated CT-Based Visceral Fat Density Predicts Mortality Regardless of Visceral Fat Area
SignalHunt:validation:Nanox
What we know · what we don’t
Everything here is open to being corrected by someone who has seen it first-hand.
What we still don’t know
Nobody has answered these yet. Your experience can help us understand what is happening.
Matters of record
Settled elsewhere. Context for reading the above, not something practice can confirm.
- 1 public external signal(s) across 1 source(s).Recorded by HealthAratus
Tool intelligence
What HealthAratus understands
HealthAratus currently understands Nanox through regulatory records and company records.
- Category
- imaging_diagnostics
What HealthAratus is still learning
HealthAratus is beginning to understand Nanox. As evidence and experience accumulate, what remains unclear will be stated here.
Evidence & claims
What this is built on
The material the questions above were built from, with its attribution.
Nanox combines a 3D tomosynthesis imaging system with AI software that analyzes routine CT scans. It identifies potential clinical findings such as osteoporosis, fatty liver disease, and coronary artery disease.According to Nanox
What Nanox states
The vendor’s own claims. Testable where practice can actually test them.
Stated capability
The AI software integrates with existing PACS and EMR systems to analyze routine CT scans.
According to Nanox
Does this change your workflow?
Independent and public evidence
Found in public sources. Not a clinician’s experience, and never presented as one.
Reported outcome
Automated CT-Based Visceral Fat Density Predicts Mortality Regardless of Visceral Fat Area
Reported publicly
Are you seeing this result?
Company participation
Not yet verified
A record of the reality forming around this technology already exists. No representative of the company has verified participation yet.
Claim your company profileReference
The stable facts, for interpreting everything above.
Overview
What it does
- Product Overview: Nanox offers a comprehensive medical imaging solution comprising the Nanox.ARC imaging system and Nanox.AI software suite. The Nanox.ARC is a digital multi-source 3D tomosynthesis system designed to produce tomographic images for various clinical applications, including musculoskeletal,…
Vendor & external product information, not independently verified by HealthAratus
Where it's used
Deployed in mixed settings
Key strength
Regulatory: FDA cleared
How the reality here has changed
Not enough recorded activity across time yet to describe how the reality here has moved. As accounts of Nanox accumulate, this becomes a record of how the reality moved rather than a snapshot of one moment.
Across the category
Nanox against the rest of Imaging & Diagnostics
Category intelligence reads this as Established. A sample of peers, not a census of the category.
Where Nanox may differ
Differences in what we have recorded. Never a ranking, never a quality judgement.
No first-hand account has been recorded for Nanox or for any peer we sampled in this category.
A gap across the whole category, not a fact about this technology.
Two readings that disagree
- Category intelligence reads clinical reality here as "Expanding", yet no first-hand account appears in the systems we sampled. Both readings are shown rather than reconciled.
Used another system in Imaging & Diagnostics? How does your experience compare?
A comparison across two systems tests the category, not just one product.
Connected intelligence
Category intelligence